US 8198254
Annexin A9 (ANXA9) biomarker and therapeutic target in epithelial cancer
granted A61KA61K31/7105
Quick answer
US patent 8198254 (Annexin A9 (ANXA9) biomarker and therapeutic target in epithelial cancer) held by The Regents of the University of California expires Mon Jun 07 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Regents of the University of California
- Grant date
- Tue Jun 12 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 07 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 5
- CPC classes
- A61K, A61K31/7105